Millennium Management LLC Acquires New Holdings in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

Millennium Management LLC purchased a new position in shares of CARGO Therapeutics, Inc. (NASDAQ:CRGX - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 96,342 shares of the company's stock, valued at approximately $1,389,000. Millennium Management LLC owned 0.21% of CARGO Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Tower Research Capital LLC TRC grew its position in shares of CARGO Therapeutics by 565.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,800 shares of the company's stock worth $84,000 after buying an additional 4,929 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of CARGO Therapeutics during the 4th quarter worth approximately $141,000. Invesco Ltd. acquired a new stake in shares of CARGO Therapeutics during the 4th quarter worth approximately $165,000. Intech Investment Management LLC acquired a new stake in shares of CARGO Therapeutics during the 4th quarter worth approximately $181,000. Finally, ExodusPoint Capital Management LP acquired a new stake in shares of CARGO Therapeutics during the 4th quarter worth approximately $183,000. Institutional investors and hedge funds own 93.16% of the company's stock.

CARGO Therapeutics Trading Up 4.2%

Shares of NASDAQ:CRGX traded up $0.19 during trading on Friday, hitting $4.75. 1,373,212 shares of the company's stock were exchanged, compared to its average volume of 562,142. CARGO Therapeutics, Inc. has a 1-year low of $3.00 and a 1-year high of $25.45. The firm has a 50-day moving average price of $4.26 and a two-hundred day moving average price of $7.85. The firm has a market cap of $219.02 million, a P/E ratio of -1.12 and a beta of 0.31.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.